Following promising results from pre-clinical and non-controlled studies, several randomized placebo-controlled trials in humans, using some of these candidates, have shown at best, modest clinical endpoints improvement or perfusion enhancing capabilities. Although therapeutic angiogenesis using angiogenesis-enhancing factors is an active research arena, it is still in its infancy and no such strategy have yet achieved acceptance as adjuvant therapy for chronic ischemic heart disease.